Scientific Publications

SG2000 Bibliography

SG2000 Bibliography

  1. Thurston D.E. (1993). Advances in the study of pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antitumor antibiotics. In: Neidle S., Waring M. J. (eds.). Molecular Aspects of Anticancer Drug-DNA Interactions (The Macmillan Press Ltd). 54-88
  2. Gregson S. J. et al.(2001).Design, synthesis and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. J Med Chem44 737-748
  3. Martin C. et al.(2005). Sequence-selective interaction of the minor-groove interstrand cross-linking agent SJG-136 with naked and cellular DNA: footprinting and enzyme inhibition studies. Biochemistry44 4135-4147
  4. Narayanaswamy M. et al.(2008). An assay combining high-performance liquid chromatography and mass spectrometry to measure DNA interstrand cross-linking efficiency in oligonucleotides of varying sequences.Anal Biochem374(1) 173-81
  5. Hartley J. A. et al.(2004). SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity. Part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity. Cancer Research 64 6693-6699
  6. Pepper C. J. et al.(2004). The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukaemia cells with evidence of a p53-independent mechanism of cell kill. Cancer Research 64 6750-6755
  7. Pepper C. et al.(2007). Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells. Br J Cancer 97(2) 253-259
  8. Clingen P. H. et al.(2005). The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136. Nucleic Acids Res 33(10) 3283-3291
  9. Gallmeier E. et al.(2006). Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options. Gastroenterology 130 2145-2154
  10. Alley M. C. et al. (2004). SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: Part 2: Efficacy evaluations. Cancer Research 64 6700-6706
  11. Reid J. M. et al.(2004). LC-MS/MS assay and rat pharmacokinetics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136. Proc Amer AssocCancer Res45 A5408
  12. Schweikart K. et al. (2004). In vitro myelosuppression of SJG-136, a pyrrolobenzodiazepine dimer: comparison to bizelesin. Proc Amer Assoc Cancer Res45 A2113
  13. Puvvada M. S. et al.(1993). A quantitative assay to measure relative DNA binding affinity of pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antitumor antibiotics based on inhibition of restriction endonuclease BamHI. Nucleic Acid Res 21 3671-3675
  14. Puvvada M. S. et al.(1997). Inhibition of bacteriophage T7 RNA polymerase in vitro transcription by DNA-binding pyrrolo[2,1- c][1,4]benzodiazepines. Biochemistry36 2478-2484
  15. Smellie M. et al.(2003). Sequence-selective recognition of duplex DNA through covalent interstrand cross-linking: kinetic and molecular modelling studies with pyrrolobenzodiazepine dimers. Biochemistry42 8232-8239
  16. Mountzouris J. A. et al.(1994). Comparison of a DSB-120 DNA interstrand cross-linked adduct with the corresponding bis-tomaymycin adducts—an example of a successful template-directed approach to drug design based upon the monoalkylating compound tomaymycin. J MedChem 37 3132-3140
  17. Jenkins T. C.  et al. (1994). Structure of a covalent DNA minor-groove adduct with a pyrrolobenzodiazepine dimers—evidence for sequence-specific interstrand cross-linking. J Med Chem 37 4529-4537
  18. Adams L. J. et al. (1999). Molecular modelling of a sequence-specific DNA-binding agent based on the pyrrolo[2,1-c][1,4]benzodiazepines. Pharm Pharmacol Commun 5 555-560   
  19. Guichard S. M. et al.(2005). Influence of P-glycoprotein expression on in vitro cytotoxicity and in vivo antitumouractivity of the novel pyrrolobenzodiazepine dimer SJG-136. Eur J Cancer41 1811-1818
  20. Wilkinson G. P. et al. (2004). Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent. Invest New Drugs22  231-240
  21. Buhrow S.A. et al.(2006). LC-MS/MS assay and dog pharmacokinetics of the dimericpyrrolobenzodiazepine SJG-136 (NSC 694501). J Chromatogr B 840 56-62

AS-1-145 (Centanamycin) publications:

  1. Yanow S. K. et al.(2008).Potent antimalarial and transmission-blocking activities of centanamycin, a novel DNA-binding agent. J Infect Dis197(4)527-534
  2. Purcell L.A. et al.(2008). Chemical attenuation of Plasmodium berghei sporozoites induces sterile immunity in mice. Infect Immun76(3) 1193-1199

Chemistry Publications:

  1. Kang G.-D. et al. (2003). Synthesis of a novel C2-aryl substituted 1,2-unsaturated pyrrolobenzodiazepine. Chem Commun14 1688-1689
  2. Cooper N. et al. (2002). Synthesis of novel C2-aryl pyrrolobenzodiazepines (PBDs) as potential antitumour agents. J Chem Soc, Chem Commun 1764-1765
  3. Berry J. M. et al. (2002). Synthesis and biological evaluation of a N10-Psec substituted pyrrolo[2,1-c][1,4]benzodiazepine prodrug. Bioorg Med Chem Lett12 1413-1416
  4. Sagnou M. J. et al. (2000). Design and synthesis of novel pyrrolobenzodiazepine (PBD) prodrugs for ADEPT and GDEPT. Bioorg Med Chem Lett10 2083-2086

SG2274 (GWL-78) Publications:

  1. Kotecha M. et al. (2008). Inhibition of DNA binding of the NF-Y transcription factor by the pyrrolobenzodiazepine-polyamide conjugate GWL-78. Mol Cancer Ther 7(5) 1319-1328